home / stock / acst / acst news

ACST News and Press, Acasti Pharma Inc. From 01/25/23

Stock Information
Company Name: Acasti Pharma Inc.
Stock Symbol: ACST
Market: NASDAQ
Website: acastipharma.com
Menu
ACST ACST Quote ACST Short ACST News ACST Articles ACST Message Board
Get ACST Alerts

News, Short Squeeze, Breakout and More Instantly...
ACST - Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

LAVAL, Québec, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces tha...
ACST - Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announc...

ACST - Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock ...

ACST - Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announc...
ACST - Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announc...

ACST - Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch

Whether you’re looking for the best penny stocks to buy now or just putting together a watch list, research is the first place to begin. Understanding why specific stocks are moving the way they are can help when applying your trading strategy to the stock market today. That’s b...

ACST - Acasti soars ~15% as phase 1 bridging study of neurodegenerative disorder drug shows promise

Acasti Pharma ( NASDAQ: ACST ) said results from a pharmacokinetic (PK) phase 1 bridging study of GTX-102 met all outcome measures. The Canadian company noted that the new formulation is aimed to improve the neurological symptoms of Ataxia Telangiectasia (A-T) in a pediatric popul...
ACST - Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces tha...

ACST - Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

LAVAL, Québec, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announc...

ACST - Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Conference Call November 14, 2022 01:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Jan D'Alvise - President & CEO Brian Ford - CFO Prashant Kohli - Chief Commercial Officer Conference Call...
Previous 10 Next 10